NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
13 trialsNCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06066424 2025-10-14
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02498912 2025-07-31
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05881525 2025-07-16
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase 1 Recruiting
NCT04643574 2025-02-14
NeoTIL in Advanced Solid Tumors
Centre Hospitalier Universitaire Vaudois
Phase 1 Active not recruiting
NCT06773091 2025-02-11
NKSOLID
Shanghai NK Cell Technology Co., LTD
Phase 1 Recruiting
NCT06394622 2024-05-01
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Fudan University
Phase 1 Recruiting
NCT06101082 2024-03-06
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
China Medical University, China
Phase 1 Recruiting
NCT06277804 2024-02-26
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
Letolab
Phase 1 Not yet recruiting
NCT03139370 2023-08-25
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT05531708 2023-03-01
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT03992326 2021-03-18
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Centre Hospitalier Universitaire Vaudois
Phase 1 Terminated